These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25211928)

  • 1. [Prognostic value of ki-67 and vimentin markers in patients with metastatic kidney cancer].
    Gorelov AI; Narimanian ZN; Gorelov DS
    Urologiia; 2014; (3):54-8. PubMed ID: 25211928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of survival rates in patients and prognostic models in non-metastatic clear-cell renal cell carcinoma].
    Iurin AG; Koval'skiĭ GB
    Arkh Patol; 2009; 71(6):15-20. PubMed ID: 20131500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
    Harada K; Miyake H; Kusuda Y; Fujisawa M
    BJU Int; 2012 Dec; 110(11 Pt C):E1131-7. PubMed ID: 22712620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
    Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
    World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
    Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
    Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy.
    Sakai I; Miyake H; Takenaka A; Fujisawa M
    BJU Int; 2009 Oct; 104(7):942-6. PubMed ID: 19388989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
    J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
    Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
    Ronkainen H; Hirvikoski P; Kauppila S; Vaarala MH
    Oncol Rep; 2011 Jan; 25(1):129-33. PubMed ID: 21109967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
    Klatte T; Seligson DB; LaRochelle J; Shuch B; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):894-900. PubMed ID: 19240241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.
    Hofmann HS; Neef H; Krohe K; Andreev P; Silber RE
    Eur Urol; 2005 Jul; 48(1):77-81; discussion 81-2. PubMed ID: 15967255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
    Itano NB; Blute ML; Spotts B; Zincke H
    J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
    Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
    Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
    J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
    Antonelli A; Arrighi N; Corti S; Legramanti S; Zanotelli T; Cozzoli A; Cunico SC; Simeone C
    BJU Int; 2012 Dec; 110(11 Pt B):E559-63. PubMed ID: 22639956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.